INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

THE NEED FOR REBLOZYL: REBLOZYL MECHANISM OF ACTION

ESA versus REBLOZYL® erythroid maturation ESA versus REBLOZYL® erythroid maturation

ESA=erythropoiesis-stimulating agent.

Erythroid and arrow icon

REBLOZYL restores erythropoiesis by increasing the number and improving the quality of mature RBCs as observed in preclinical studies1

  • REBLOZYL binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and increasing the number of mature RBCs1,6,7
  • In preclinical models, REBLOZYL improved1,8:
    • Hgb levels
    • RBC morphology
    • Other hematology parameters* associated with ineffective erythropoiesis

*Other hematology parameters include reducing oxidative stress in erythrocytes, reducing accumulation of α-globin aggregates in erythrocyte membranes, and improving RBC life span.

Hgb=hemoglobin; RBC=red blood cell; TGF-beta=transforming growth factor beta.

THE NEED FOR REBLOZYL: REBLOZYL MECHANISM OF ACTION

ESA versus REBLOZYL® erythroid maturation ESA versus REBLOZYL® erythroid maturation

ESA=erythropoiesis-stimulating agent.

Erythroid and arrow icon

REBLOZYL restores erythropoiesis by increasing the number and improving the quality of mature RBCs as observed in preclinical studies1

  • REBLOZYL binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and increasing the number of mature RBCs1,6,7
  • In preclinical models, REBLOZYL improved1,8:
    • Hgb levels
    • RBC morphology
    • Other hematology parameters* associated with ineffective erythropoiesis

*Other hematology parameters include reducing oxidative stress in erythrocytes, reducing accumulation of α-globin aggregates in erythrocyte membranes, and improving RBC life span.

Hgb=hemoglobin; RBC=red blood cell; TGF-beta=transforming growth factor beta.

References: 1. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2022. 2. Liang R, Ghaffari S. Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease. Br J Haematol. 2016;174(5):661-673. 3. Elliott S and Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics. 2012;6:163-189. 4. Elliott S, Phama E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol. 2008;36:1573-1584. 5. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96(6):2022-2036. 6. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414. 7. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770. 8. Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014;123(25):3864-3872.